Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTHONY M CIABARRA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1942374392
CMS profile
133347
Location
FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,123.63

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,123.63 57

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTHONY M CIABARRA

NPI 1942374392 · CMS profile ID 133347

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942374392?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTHONY M CIABARRA, NPI 1942374392, CMS profile ID 133347. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942374392?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANTHONY M CIABARRA, NPI 1942374392, CMS profile ID 133347. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942374392?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANTHONY M CIABARRA, NPI 1942374392, CMS profile ID 133347, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1942374392?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $1,123.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–57 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $25.1102/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619257 CMS
Abbott Laboratories $19.8102/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125349278 CMS
ABBVIE INC. $5.4502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103473767 CMS
Lilly USA, LLC $23.5702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136000059 CMS
ABBVIE INC. $2.3801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103473765 CMS
Alexion Pharmaceuticals, Inc. $19.0201/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093937860 CMS
TG Therapeutics, Inc. $23.2401/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136877134 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $482.59 35
PY2020 $257.58 26
PY2021 $515.91 34
PY2022 $464.88 27
PY2023 $1,137.92 57
PY2024 $1,123.63 57
PY2025 $579.46 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $332,486.45 105
PY2024 Principal investigator $859,367.55 115
PY2023 Recipient $3,288.22 4
PY2023 Principal investigator $1,155,428.79 46
PY2022 Recipient $1,620.00 2
PY2022 Principal investigator $1,158,108.87 34
PY2021 Recipient $7,802.31 3
PY2021 Principal investigator $808,027.02 21
PY2020 Principal investigator $610,490.44 51
PY2019 Recipient $2,853.77 1
PY2019 Principal investigator $557,286.84 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

105 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $6,500.00 12/18/2025 Non-covered Recipient Entity
STEPHEN R WALDMAN MD PHD INC
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187892568
Principal investigator 1 Ipsen Innovation $90.00 12/15/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288146
Principal investigator 1 Ipsen Innovation $180.00 12/15/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288148
Principal investigator 1 Ipsen Innovation $150.00 12/15/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288150
Principal investigator 1 Eisai Inc. $33,514.20 11/20/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560172
Principal investigator 1 H. Lundbeck A S $4,608.00 11/20/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251777544
Principal investigator 1 H. Lundbeck A S $3,400.00 11/20/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251777549
Principal investigator 1 H. Lundbeck A S $7,500.00 11/20/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251777552
Principal investigator 1 Roche TCRC, Inc. $3,668.40 11/13/2025 Non-covered Recipient Entity
NEUROLOGY CENTER NORTH ORANGE COUNTY
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211627709
Principal investigator 1 Ipsen Innovation $150.00 11/12/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288142
Principal investigator 1 Ipsen Innovation $90.00 11/12/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288144
Principal investigator 1 Novartis Pharmaceuticals Corporation $102.60 10/28/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304563
Principal investigator 1 Ipsen Innovation $2,882.25 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288116
Principal investigator 1 Ipsen Innovation $81.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288118
Principal investigator 1 Ipsen Innovation $81.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288120
Principal investigator 1 Ipsen Innovation $1,113.75 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288122
Principal investigator 1 Ipsen Innovation $2,232.90 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288124
Principal investigator 1 Ipsen Innovation $81.00 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288126
Principal investigator 1 Ipsen Innovation $1,636.20 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288128
Principal investigator 1 Ipsen Innovation $1,046.25 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288130
Principal investigator 1 Ipsen Innovation $1,046.25 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288132
Principal investigator 1 Ipsen Innovation $1,046.25 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288134
Principal investigator 1 Ipsen Innovation $1,636.20 10/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288140
Principal investigator 1 Eisai Inc. $1,535.40 10/24/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560170
Principal investigator 1 Ipsen Innovation $90.00 10/21/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288136
Principal investigator 1 Ipsen Innovation $450.00 10/21/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288138
Principal investigator 1 Roche TCRC, Inc. $11,692.80 10/15/2025 Non-covered Recipient Entity
NEUROLOGY CENTER NORTH ORANGE COUNTY
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211627706
Principal investigator 1 Ipsen Innovation $470.00 09/19/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288114
Principal investigator 1 Roche TCRC, Inc. $1,746.00 09/11/2025 Non-covered Recipient Entity
NEUROLOGY CENTER NORTH ORANGE COUNTY
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211627702
Principal investigator 1 Ipsen Innovation $1,780.65 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288080
Principal investigator 1 Ipsen Innovation $81.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288082
Principal investigator 1 Ipsen Innovation $1,046.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288084
Principal investigator 1 Ipsen Innovation $2,232.90 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288086
Principal investigator 1 Ipsen Innovation $1,840.05 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288088
Principal investigator 1 Ipsen Innovation $2,882.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288090
Principal investigator 1 Ipsen Innovation $81.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288092
Principal investigator 1 Ipsen Innovation $1,046.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288094
Principal investigator 1 Ipsen Innovation $1,046.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288096
Principal investigator 1 Ipsen Innovation $1,046.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288098
Principal investigator 1 Ipsen Innovation $1,046.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288100
Principal investigator 1 Ipsen Innovation $1,046.25 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288102
Principal investigator 1 Ipsen Innovation $81.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288104
Principal investigator 1 Ipsen Innovation $1,113.75 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288106
Principal investigator 1 Ipsen Innovation $180.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288110
Principal investigator 1 Ipsen Innovation $150.00 08/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288112
Principal investigator 1 Ipsen Innovation $90.00 08/25/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288108
Principal investigator 1 Roche TCRC, Inc. $5,758.20 08/14/2025 Non-covered Recipient Entity
NEUROLOGY CENTER NORTH ORANGE COUNTY
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211627697
Principal investigator 1 Ipsen Innovation $1,840.05 07/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288068
Principal investigator 1 Ipsen Innovation $2,232.90 07/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288070
Principal investigator 1 Ipsen Innovation $2,882.25 07/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288072
Principal investigator 1 Ipsen Innovation $1,046.25 07/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288074
Principal investigator 1 Ipsen Innovation $1,046.25 07/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288076
Principal investigator 1 Ipsen Innovation $1,113.75 07/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288078
Principal investigator 1 Ipsen Innovation $300.00 07/25/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288058
Principal investigator 1 Ipsen Innovation $150.00 07/16/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288064
Principal investigator 1 Ipsen Innovation $150.00 07/16/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288066
Principal investigator 1 Ipsen Innovation $150.00 07/15/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288060
Principal investigator 1 Ipsen Innovation $300.00 07/15/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288062
Principal investigator 1 Ipsen Innovation $81.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288038
Principal investigator 1 Ipsen Innovation $1,046.25 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288040
Principal investigator 1 Ipsen Innovation $1,046.25 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288042
Principal investigator 1 Ipsen Innovation $1,046.25 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288044
Principal investigator 1 Ipsen Innovation $1,046.25 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288046
Principal investigator 1 Ipsen Innovation $81.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288048
Principal investigator 1 Ipsen Innovation $81.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288050
Principal investigator 1 Ipsen Innovation $2,882.25 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288052
Principal investigator 1 Ipsen Innovation $81.00 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288054
Principal investigator 1 Ipsen Innovation $2,232.90 06/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288056
Principal investigator 1 Roche TCRC, Inc. $31,898.70 06/13/2025 Non-covered Recipient Entity
NEUROLOGY CENTER NORTH ORANGE COUNTY
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211627692
Principal investigator 1 Ipsen Innovation $270.00 05/20/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288034
Principal investigator 1 Ipsen Innovation $450.00 05/20/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288036
Principal investigator 1 Genentech, Inc. $32,299.00 05/16/2025 Non-covered Recipient Entity
NEUROLOGY CTR OF NORTH ORANGE COUNTY A MEDICAL CORP
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211628015
Principal investigator 1 H. Lundbeck A S $3,554.00 05/08/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770113
Principal investigator 1 Ipsen Innovation $1,046.25 04/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287992
Principal investigator 1 Ipsen Innovation $1,046.25 04/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288012
Principal investigator 1 Ipsen Innovation $1,046.25 04/30/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288014
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287990
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287994
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287996
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287998
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288000
Principal investigator 1 Ipsen Innovation $1,780.65 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288002
Principal investigator 1 Ipsen Innovation $1,780.65 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288004
Principal investigator 1 Ipsen Innovation $1,636.20 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288006
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288008
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288010
Principal investigator 1 Ipsen Innovation $81.00 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288016
Principal investigator 1 Ipsen Innovation $1,840.05 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288018
Principal investigator 1 Ipsen Innovation $1,780.65 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288020
Principal investigator 1 Ipsen Innovation $2,124.90 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288022
Principal investigator 1 Ipsen Innovation $1,046.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288024
Principal investigator 1 Ipsen Innovation $2,882.25 04/28/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288026
Principal investigator 1 Ipsen Innovation $600.00 04/17/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288030
Principal investigator 1 Ipsen Innovation $270.00 04/17/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288032
Principal investigator 1 Ipsen Innovation $481.40 04/09/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288028
Principal investigator 1 Eli Lilly and Company $46,796.00 03/25/2025 Non-covered Recipient Entity
STEPHEN R WALDMAN MD PHD INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187890710
Principal investigator 1 H. Lundbeck A S $3,554.00 02/20/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767555
Principal investigator 1 Ipsen Innovation $90.00 01/31/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287944
Principal investigator 1 Novartis Pharmaceuticals Corporation $307.80 01/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304565
Principal investigator 1 H. Lundbeck A S $816.85 01/29/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766752
Principal investigator 1 Eli Lilly and Company $816.00 01/28/2025 Non-covered Recipient Entity
STEPHEN R WALDMAN MD PHD INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890306
Principal investigator 1 Ipsen Innovation $2,124.90 01/27/2025 Non-covered Recipient Entity
Neurology Center Of North Orange County
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287980
Principal investigator 1 UCB SA $38,580.00 01/23/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY AND OSTEOPOROSIS MEDICAL GROUP, INC
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246659152
Principal investigator 1 Roche TCRC, Inc. $9,526.50 01/16/2025 Non-covered Recipient Entity
NEUROLOGY CENTER NORTH ORANGE COUNTY
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211627686
Principal investigator 1 H. Lundbeck A S $2,431.85 01/03/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF NORTH ORANGE COUNTY A MEDICAL CORP
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766128